Pipeline Lundbeck preps for key bexicaserin data around year-end PharmaphorumLundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.NeuroscienceRead full story pharminent July 20, 2026 (Last updated: July 20, 2026) Pharmaphorum Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Converts Novartis’ Fabhalta to Full Approval in IgA NephropathyNext: Samsung Biologics Acquires Swiss CDMO PolyPeptide in $1.81bn All-Cash Deal Related Stories Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026 Pipeline Roche scraps two Ionis-partnered Huntington’s drugs pharminent July 9, 2026 Pipeline Keenova eyes Xiaflex as first drug for plantar fibromatosis pharminent July 9, 2026
